2007 Sales: $3.2 billion
Market share: 4.3%
What they have: Sanofi's top-selling biotech blockbuster is Lantus, a Type 1 and 2 diabetes treatment. The company also markets a host of vaccines through Sanofi Pasteur, the vaccine division of Sanofi-Aventis.
What to look for: Currently, only 10 percent of the drugs Sanofi makes are biologics; in an interview, Senior Vice President, Scientific and Medical Affairs Mark Cluzel said the company wants to boost that number to 20 or 30 percent by 2012. Sanofi is collaborating with Regeneron on its drug Aflibercept (VEGF Trap), a cancer drug in late-stage trials for prostate and lung cancer.